366 related articles for article (PubMed ID: 34745955)
1. Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis.
Huang M; Li J; Yu X; Xu Q; Zhang X; Dai X; Li S; Sheng L; Huang K; Liu L
Front Oncol; 2021; 11():734323. PubMed ID: 34745955
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis.
Zhang C; Xiang Y; Wang J; Yan D
Front Oncol; 2023; 13():1118820. PubMed ID: 36937403
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
Park S; Nam CM; Kim SG; Mun JE; Rha SY; Chung HC
Eur J Cancer; 2021 Feb; 144():49-60. PubMed ID: 33338727
[TBL] [Abstract][Full Text] [Related]
5. PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.
Guo X; Yang B; He L; Sun Y; Song Y; Qu X
Front Immunol; 2022; 13():905651. PubMed ID: 36003374
[TBL] [Abstract][Full Text] [Related]
6. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
[TBL] [Abstract][Full Text] [Related]
7. What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis.
Zhang X; Xu Q; Yu X; Huang M; Li S; Sheng L; Dai X; Huang K; Wang J; Liu L
Front Immunol; 2022; 13():764643. PubMed ID: 35450068
[TBL] [Abstract][Full Text] [Related]
8. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
9. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
10. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials.
Pan S; Li K; Huang B; Huang J; Xu H; Zhu Z
Ann Transl Med; 2021 Feb; 9(4):290. PubMed ID: 33708917
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Wang Z; Zhou F; Xu S; Wang K; Ding H
Cancer Med; 2023 Sep; 12(18):18516-18530. PubMed ID: 37584242
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian network meta-analysis on systemic therapy for previously treated gastric cancer.
Kim JH; Zang DY; Jang HJ; Kim HS
Crit Rev Oncol Hematol; 2021 Nov; 167():103505. PubMed ID: 34656747
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
[TBL] [Abstract][Full Text] [Related]
16. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
Janjua S; Mathioudakis AG; Fortescue R; Walker RA; Sharif S; Threapleton CJ; Dias S
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013198. PubMed ID: 33448349
[TBL] [Abstract][Full Text] [Related]
19. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N; Xu Y; Wilson FR; Guyot P; Chen CI; Keeping S; Konidaris G; Chan K; Kuznik A; Atsou K; Glowienka E; Pouliot JF; Gullo G; Rietschel P
Ther Adv Med Oncol; 2022; 14():17588359221105024. PubMed ID: 35747163
[TBL] [Abstract][Full Text] [Related]
20. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
Zheng J; Huang B; Xiao L; Wu M; Li J
Front Oncol; 2022; 12():821626. PubMed ID: 36568203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
